1. Home
  2. MTEK vs BNR Comparison

MTEK vs BNR Comparison

Compare MTEK & BNR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Maris-Tech Ltd.

MTEK

Maris-Tech Ltd.

HOLD

Current Price

$1.55

Market Cap

12.6M

Sector

N/A

ML Signal

HOLD

Logo Burning Rock Biotech Limited

BNR

Burning Rock Biotech Limited

HOLD

Current Price

$29.18

Market Cap

216.9M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
MTEK
BNR
Founded
2008
2014
Country
Israel
China
Employees
N/A
N/A
Industry
Medical Specialities
Sector
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
12.6M
216.9M
IPO Year
2022
2020

Fundamental Metrics

Financial Performance
Metric
MTEK
BNR
Price
$1.55
$29.18
Analyst Decision
Analyst Count
0
0
Target Price
N/A
N/A
AVG Volume (30 Days)
101.9K
23.5K
Earning Date
03-30-2026
03-24-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$3,375,716.00
$75,749,382.00
Revenue This Year
N/A
$136.32
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
5.56
52 Week Low
$1.03
$2.18
52 Week High
$4.27
$41.72

Technical Indicators

Market Signals
Indicator
MTEK
BNR
Relative Strength Index (RSI) 49.90 50.03
Support Level $1.48 $28.28
Resistance Level $1.65 $34.26
Average True Range (ATR) 0.18 3.24
MACD -0.02 -1.11
Stochastic Oscillator 14.08 15.56

Price Performance

Historical Comparison
MTEK
BNR

About MTEK Maris-Tech Ltd.

Maris Tech Ltd is a business-to-business approach, or B2B provider of remote video, audio, telemetry acquisition, distribution, and sharing solutions and products, using high-end digital video, audio, and wireless communication technologies. It designs, develops, manufactures and commercially sells miniature intelligent video and audio surveillance and communication systems, which are offered as products and solutions for the professional as well as the civilian and home security markets.

About BNR Burning Rock Biotech Limited

Burning Rock Biotech Ltd is a cancer diagnostics company. It is a NGS-based cancer therapy selection company. Its cancer therapy selection platform is built upon advanced proprietary technologies, comprehensive portfolio of products and a two-pronged market-driven commercial infrastructure addressing both larger hospitals through company's in-hospital model and smaller hospitals through its central laboratory model. It had three operating segments, including Central laboratory business, In-hospital business and Pharma research and development services. It generates the majority of its revenue from Central laboratory business. Its products are Pan-HEME, OncoScreen-WES, brPROPHET, OncoScreen Plus, and others.

Share on Social Networks: